Alliance for Pandemic Preparedness

July 7, 2020

Tocilizumab in patients with severe COVID‐19: A single‐center observational analysis

Category:

Topic:

  • Knorr et al. find limited clinical improvement in 66 patients with severe COVID‐19 who received tocilizumab. Within 14 days of treatment, 29% of patients had clinical improvement, 20% had minimal or no improvement, 17% worsened, 27% died, and 7% were transferred to an outside hospital. Ultimately, 42% of all patients who received tocilizumab died and 49% were discharged. 

Knorr et al. (June 17, 2020). Tocilizumab in patients with severe COVID‐19: A single‐center observational analysis. Journal of Medical Virology. https://doi.org/10.1002/jmv.26191